- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab ; volume:12 ; number:2 ; year:2019 ; pages:621-624
Case reports in oncology ; 12, Heft 2 (2019), 621-624
- Urheber
-
Tonk, Erwin H.J.
van Lindert, Anne S.R.
Verhoeff, Joost J.C.
Suijkerbuijk, Karijn P.M.
- DOI
-
10.1159/000502202
- URN
-
urn:nbn:de:101:1-2019091200470320912636
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tonk, Erwin H.J.
- van Lindert, Anne S.R.
- Verhoeff, Joost J.C.
- Suijkerbuijk, Karijn P.M.
Ähnliche Objekte (12)
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
Early onset recall pneumonitis during targeted therapy with sunitinib
Lethal Immune-Related Pneumonitis after Durvalumab Therapy for Small Cell Lung Cancer: A First Case in China
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
Arzneimittel Profil Durvalumab
Hypersensitivity pneumonitis
RADIATION PNEUMONITIS
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis
Retinal Vasculitis Secondary to Durvalumab
Novel acute hypersensitivity pneumonitis model induced by airway mycosis and high dose lipopolysaccharide
High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
Early onset recall pneumonitis during targeted therapy with sunitinib
Lethal Immune-Related Pneumonitis after Durvalumab Therapy for Small Cell Lung Cancer: A First Case in China
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
Arzneimittel Profil Durvalumab
Hypersensitivity pneumonitis
RADIATION PNEUMONITIS
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis
Retinal Vasculitis Secondary to Durvalumab
Novel acute hypersensitivity pneumonitis model induced by airway mycosis and high dose lipopolysaccharide
High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
Early onset recall pneumonitis during targeted therapy with sunitinib
Lethal Immune-Related Pneumonitis after Durvalumab Therapy for Small Cell Lung Cancer: A First Case in China
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
Arzneimittel Profil Durvalumab
Hypersensitivity pneumonitis
RADIATION PNEUMONITIS
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis
Retinal Vasculitis Secondary to Durvalumab
Novel acute hypersensitivity pneumonitis model induced by airway mycosis and high dose lipopolysaccharide